Patience David 4

What Happened
Patience David, Chief Financial Officer of TriSalus Life Sciences, reported an outright purchase of 7,100 shares of TLSI common stock on 2026-05-15. The shares were acquired at $2.43 per share for a total reported value of $17,253. The Form 4 reporting this transaction was filed with the SEC on 2026-05-18. This was a purchase (transaction code P), which is an acquisition of stock rather than a sale.

Key Details

• Transaction date: 2026-05-15; Filing date: 2026-05-18 (timely filing).
• Price and amount: 7,100 shares @ $2.43 each = $17,253 total.
• Transaction code: P (purchase; open market or private purchase as reported).
• Shares owned after transaction: Not specified in the filing.
• Footnotes / plans: No 10b5-1 plan, tax withholding, or other footnotes referenced in the report.

Context
This report documents a direct purchase of company stock by a named executive. Purchases are often of interest because they represent an insider acquiring shares, but filings are factual records and do not explain motivation.